Compare LOAN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOAN | ANL |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 52.0M |
| IPO Year | 1999 | 2023 |
| Metric | LOAN | ANL |
|---|---|---|
| Price | $4.78 | $1.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.1K | 10.1K |
| Earning Date | 10-24-2025 | 11-07-2025 |
| Dividend Yield | ★ 9.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $7,138,128.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $10.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.29 | $1.10 |
| 52 Week High | $6.05 | $2.99 |
| Indicator | LOAN | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 33.11 |
| Support Level | $4.64 | $1.32 |
| Resistance Level | $4.74 | $1.59 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 74.04 | 0.00 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.